Maprotiline is a tetracyclic antidepressant used clinically for the treatment of various types of depression, particularly effective in patients with anxiety and depressive states induced by physical illness or psychological factors; it is also used in children with depressive and agitated behavioral disorders and in the management of nocturnal enuresis. It exhibits significant anti-proliferative activity against hepatocellular carcinoma both in vitro and in vivo, demonstrating potential as a novel therapeutic agent for liver cancer. Additionally, maprotiline has shown anti-tumor effects in prostate cancer, Burkitt lymphoma (by inducing type II autophagic cell death), and glioblastoma, and it induces apoptosis in Neuro-2a cells via activation of the JNK-related caspase-3 pathway.